Stock analysts at Benchmark Co. initiated coverage on shares of Natus Medical Inc. (NASDAQ:BABY) in a report issued on Tuesday. The brokerage set a “buy” rating and a $55.00 price target on the stock. Benchmark Co.’s price objective indicates a potential upside of 35.84% from the company’s current price.
A number of other analysts also recently commented on the company. Raymond James Financial Inc. raised Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective on the stock in a research note on Tuesday, September 13th. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a research note on Thursday, July 7th.
Shares of Natus Medical (NASDAQ:BABY) opened at 40.49 on Tuesday. Natus Medical has a 52 week low of $29.54 and a 52 week high of $51.05. The firm has a 50-day moving average price of $40.51 and a 200-day moving average price of $36.85. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 34.91 and a beta of 0.78.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.03. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The company earned $96 million during the quarter, compared to analyst estimates of $92.71 million. During the same quarter in the previous year, the firm posted $0.34 EPS. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities analysts expect that Natus Medical will post $1.58 earnings per share for the current fiscal year.
In related news, insider James B. Hawkins bought 10,000 shares of the business’s stock in a transaction dated Wednesday, September 28th. The shares were bought at an average cost of $38.48 per share, with a total value of $384,800.00. Following the completion of the transaction, the insider now directly owns 459,725 shares of the company’s stock, valued at $17,690,218. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.80% of the company’s stock.
Large investors have recently made changes to their positions in the company. Acrospire Investment Management LLC raised its stake in shares of Natus Medical by 39.1% in the second quarter. Acrospire Investment Management LLC now owns 2,844 shares of the company’s stock worth $108,000 after buying an additional 800 shares during the period. BlackRock Inc. raised its stake in shares of Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock worth $117,000 after buying an additional 820 shares during the period. Invictus RG bought a new stake in shares of Natus Medical during the first quarter worth about $148,000. PineBridge Investments L.P. raised its stake in shares of Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock worth $159,000 after buying an additional 149 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in shares of Natus Medical by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 4,602 shares of the company’s stock worth $174,000 after buying an additional 562 shares during the period. 87.92% of the stock is currently owned by institutional investors.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.